New york, Nov. 18, 2019 (GLOBE NEWSWIRE) — High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding scenario, and drug development pressure on pharmaceuticals due to upcoming patent expiries are key factors contributing to high CAGR of Idiopathic Thrombocytopenic Purpura Therapeutics during forecast period.
According to the current analysis of Reports and Data, the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market was valued at USD 498 Million in 2018 and is expected to reach USD 783 Million by year 2026, at a CAGR of 5.8 %. The study covers therapeutic agents for ‘Idiopathic thrombocytopenic purpura’ – Idiopathic thrombocytopenic purpura is a hematologic disorder, caused due to abnormal decrease in the platelet count. It is clinically diagnosed as acquired bleeding disorder in which platelets (blood cells), who play a vital role in primary and secondary haemostasis are destroyed by immune system.
Rising prevalence of target diseases, unmet needs of Idiopathic thrombocytopenic purpura patients pushing the drug development, significant focus of pharmaceutical companies on development of novel mechanisms based Idiopathic thrombocytopenic purpura drugs, upcoming patent expiry, availability of public as well private funds for research, and favorable regulatory scenario, are some of the key factors propelling market growth in the industry. However, associated side effects, and lack of awareness of disease, are the major hindrance for market growth during 2019 – 2026.
Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2197
Further key findings from the report suggest
- Idiopathic Thrombocytopenic Purpura Therapeutics market is growing at a CAGR of 3 % in North America followed by Asia Pacific and Europe, respectively. High disease prevalence across the globe is the prominent factor to accelerate the market growth during the forecast period across all regions
- As of 2018, Product type segment, Corticosteroids is the dominating Idiopathic Thrombocytopenic Purpura Therapeutics which holds 35.5 % of the global market. European regional market is the prominent revenue generating source for this product segment, followed by North America, Asia-Pacific, and other regions
- Anti-D immunoglobulin product type segment is expected to be the fastest growing market segment during the forecast period 2019 – 2026 with a CAGR of 6.6 %. However, associated side effects and high costs are major restraints for the market growth of this market segment
- Retail pharmacies distribution channels type segment was growing at an appreciable CAGR during the forecast period
- Asia Pacific is expected to account for the 19.2 % of the global Idiopathic Thrombocytopenic Purpura Therapeutics market. Developing nations such China, and India are likely to witness high growth owing it to growing awareness about the disease and untapped market potential
- Europe regional segment is anticipated to witness significant growth during the forecast period 2019 – 2026. The regional segment was valued at second highest in the year 2018, and is expected to reach upwards of USD 200 million by the year 2026
- Associated side effects related to Idiopathic Thrombocytopenic Purpura Therapeutics and lack of awareness about pruritus is likely to hinder the market growth during the forecast period
- Key participants include Hoffman-L Roche, Novartis, GlaxoSmithKline, Eisai, Amgen, Grifols Biologicals Inc., Baxter, CSL Behring, Bristol-Myers Squibb, Roxane, and others
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/idiopathic-thrombocytopenic-purpura-itp-therapeutics-market
Segments covered in the report:
For the purpose of this report, Reports and Data has segmented the Idiopathic Thrombocytopenic Purpura Therapeutics market on the basis of Product type, Distribution channels type, treatment type, and region:
Product Type of Idiopathic Thrombocytopenic Purpura Therapeutics (Revenue, USD Million; 2016–2026)
- Corticosteroids
- Intravenous immunoglobulins
- Anti-D immunoglobulin
- Thrombopoietin receptor agonists (TPO-RA)
- Others
Distribution channels Type of Idiopathic Thrombocytopenic Purpura Therapeutics (Revenue, USD Million; 2016–2026)
- Drug store
- Retail pharmacies
- Others
Treatment Type of Idiopathic Thrombocytopenic Purpura Therapeutics (Revenue, USD Million; 2016–2026)
- Oral corticosteroids
- Prednisone
- Rituximab
- Azathioprine
- Eltrombopag
- Spleenectomy
- Intravenous immunoglobulin (IVIG)
- Anti-D immunoglobulin
- Thrombopoietin receptor agonists
Order Now: https://www.reportsanddata.com/checkout-form/2197
Regional Outlook of Idiopathic Thrombocytopenic Purpura Therapeutics (Revenue in USD Million; 2016–2026)
- North America
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Middle East & Africa
- Brazil
Browse more similar reports on Medical Devices category by Reports And Data
Dental X-Ray Market – https://www.reportsanddata.com/report-detail/dental-x-ray-market
Artificial Ventilators and Anesthesia Masks Market – https://www.reportsanddata.com/report-detail/artificial-ventilators-and-anesthesia-masks-market
Apheresis Equipment Market – https://www.reportsanddata.com/report-detail/apheresis-equipment-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: [email protected]
